Description:TECHNICAL FIELD
The present disclosure relates to lightening hyperpigmented skin. More particularly, the present disclosure relates to a method of preparing a formulation and a kit for lightening hyperpigmented skin. More particularly, the present disclosure relates to a method of preparing a formulation and a kit for Melasma.
BACKGROUND
Melasma is a common acquired skin disorder characterized by symmetrical hyperpigmented patches, primarily affecting sun-exposed areas such as the cheeks, forehead, upper lip, nose, and chin. It predominantly affects women, particularly those of Asian, Latin American, Middle Eastern, and African descent with Fitzpatrick skin types III to VI. Studies indicate that melasma affects up to 40% of Southeast Asian populations. While its exact cause remains unclear, genetic predisposition, chronic sun exposure, pregnancy, oral contraceptive use, and certain antiepileptic drugs are recognized as key contributing factors. Beyond its physical manifestations, melasma can significantly impact psychological well-being, leading to feelings of shame, low self-esteem, social withdrawal, and depression.
Presently available treatments, such as Kligman’s formula—a combination of hydroquinone, retinoids, and corticosteroids—remain widely used but have notable drawbacks. Despite their effectiveness, these treatments often lead to a rebound effect, where hyperpigmentation returns upon discontinuation. Various therapeutic agents, including both plant-derived and synthetic compounds, have been explored to target different stages of melanin production. These include tyrosinase inhibitors, which suppress melanin synthesis, agents that block melanosome transfer to keratinocytes, and compounds that accelerate skin cell turnover. However, present therapies primarily address melasma as a pigmentary disorder driven by overactive melanocytes, overlooking underlying factors such as photoaging. In addition to the rebound effect, conventional treatments for melasma often cause skin irritation, redness, and increased sensitivity, particularly with prolonged use of hydroquinone and retinoids. Corticosteroids, if overused, can lead to skin thinning, telangiectasia (visible blood vessels), and steroid-induced acne. Moreover, many treatments require long-term adherence, and their efficacy varies based on individual skin type, making consistent and predictable outcomes challenging.
Therefore, there is a need for a method of preparing formulation and a kit for lightening hyperpigmented skin to overcome aforementioned problems.
SUMMARY
In an aspect of the present disclosure, a method of preparing a formulation for lightening hyperpigmented skin is disclosed. The method include steps: combining one or more ingredients, wherein one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4-8% w/v, 4-n-tert-butylresorcinol in a range of 0.05-2% w/v, quercetin in a range of 0.2-0.8% w/v, ceramides in a range of 0.05-0.7% w/v, lavender essential oil in a range of 0.05-0.7% w/v, all-trans-retinal in a range of 0.01-0.1% w/v, ethanol in a range of 0.5-3% w/v, niacinamide in a range of 0.05-4% w/v, tranexamic acid in a range of 0.05-5% w/v, glutathione in a range of 1-4% w/v, ascorbic acid in a range of 0.2-2% w/v, sodium ascorbate in a range of 0.1-3% w/v, sodium metabisulphite in a range of 0.01-0.5% w/v, glycerol in a range of 0.5-3% w/v, propylene glycol in a range of 0.5-3% w/v, xanthan gum in a range of 0.01-2% w/v, acacia in a range of 0.01-2% w/v, poloxamer 407 in a range of 0.01-0.5% w/v, and potassium sorbate in a range of 0.1-0.3% w/v. The method further includes dissolving non-GMO sunflower phosphatidylcholine H90 in a range of 4-8% w/v, 4-n-tert-butylresorcinol in a range of 0.05-2% w/v, quercetin in a range of 0.2-0.8% w/v, ceramides in a range of 0.05-0.7% w/v, lavender essential oil in a range of 0.2-1% w/v, and all-trans-retinal in a range of 0.01-0.1% w/v in ethanol in a range of 0.5-3% w/v to obtain a mixture. Furthermore, the method includes pouring the mixture into a flask and heating the mixture at a temperature in a range of 20°C to 40°C for evaporating residual ethanol, to form a thin lipid film. Furthermore, the method further includes hydrating the lipid film by adding an aqueous phase, wherein the aqueous phase comprises niacinamide in a range of 0.05-4% w/v, tranexamic acid in a range of 0.05-5% w/v, glutathione in a range of 1-4% w/v, ascorbic acid in a range of 0.2-2% w/v and as sodium ascorbate in a range of 0.1-3% w/v, sodium metabisulphite in a range of 0.01-0.5% w/v, glycerol in a range of 0.5-3% w/v, propylene glycol in a range of 0.5-3% w/v, xanthan gum in a range of 0.01-2% w/v, acacia in a range of 0.01-2% w/v, poloxamer 407 in a range of 0.01-0.5% w/v, and potassium sorbate in a range of 0.01-2% w/v, and heating at a temperature in a range of 20°C to 40°C to convert the lipid film into a hydrated liposome suspension. Furthermore, the method includes, sonicating the hydrated liposome suspension at a temperature of 10°C to 20°C, followed by homogenizing the obtained liposome suspension at a speed of 10,000 to 15,000 rpm to further reduce liposome size and adjusting pH in a range of 5 to 5.5, to obtain a final formulation for lightening hyperpigmented skin.
In some aspects, the method further includes filtering the final formulation through a 0.22 µm filter.
In some aspects the formulation includes, serum 1 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, 4-n-tert-butylresorcinol in a range of 0.05 % w/v to 2 % w/v, niacinamide in a range of 0.05 % w/v to 4 % w/v, tranexamic acid in a range of 0.05 % w/v to 5 % w/v, acacia in a range of 0.01 % w/v to 0.5 % w/v, xanthan gum in a range of 0.01 % w/v to 0.5 % w/v, and potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and ultra-pure water. Serum 2 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, glutathione in a range of 1 % w/v to 4 % w/v, ascorbic acid in a range of 0.2 % w/v to 2 % w/v, sodium ascorbate in a range of 0.1 % w/v to 3 % w/v, sodium metabisulfite in a range of 0.01 % w/v to 0.5 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and lavender essential oil in a range of 0.2 % w/v to 1 % w/v, and ultra-pure water; and Serum 3 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, all-trans-retinal in a range of 0.01 % w/v to 0.1 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, and potassium sorbate in a range of 0.01 % w/v to 2 % w/v, and ultra-pure water.
In an aspect, a kit for lightening hyperpigmented skin is disclosed. The kit includes the formulation. The formulation includes serum 1, serum 2, and serum 3. Serum 1 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, 4-n-tert-butylresorcinol in a range of 0.05 % w/v to 2 % w/v, niacinamide in a range of 0.05 % w/v to 4 % w/v, tranexamic acid in a range of 0.05 % w/v to 5 % w/v, acacia in a range of 0.01 % w/v to 0.5 % w/v, xanthan gum in a range of 0.01 % w/v to 0.5 % w/v, and potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and ultra-pure water; serum 2 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, glutathione in a range of 1 % w/v to 4 % w/v, ascorbic acid in a range of 0.2 % w/v to 2 % w/v, sodium ascorbate in a range of 0.1 % w/v to 3 % w/v, sodium metabisulfite in a range of 0.01 % w/v to 0.5 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and lavender essential oil in a range of 0.2 % w/v to 1 % w/v, and ultra-pure water; serum 3 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, all-trans-retinal in a range of 0.01 % w/v to 0.1 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, and potassium sorbate in a range of 0.01 % w/v to 2 % w/v, and ultra-pure water.
In an aspect, a method for treating hyperpigmented skin is disclosed. The method includes topically administering the formulation. The formulation includes serum 1, serum 2, and serum 3. The method further includes applying the formulation to the hyperpigmented skin topically to reduce pigmentation in the affected areas of the skin.
In an aspect, use of the formulation may be for lightening hyperpigmented skin conditions is disclosed.
BRIEF DESCRIPTION OF THE DRAWING
The above and still further features and advantages of aspects of the present disclosure become apparent upon consideration of the following detailed description of aspects thereof, especially when taken in conjunction with the accompanying drawings, and wherein:
FIG. 1 illustrates a flowchart that depicts a method of preparing formulation for lightening hyperpigmented skin, in accordance with an aspect of the present disclosure.
FIG. 2 illustrates the observation of the clinical trials on the individuals, in accordance with an exemplary aspect the present disclosure.
FIG. 3A illustrates a graphical representation of dermatologist-assessed efficacy (mMASI Scoring) of the clinical trials, in accordance with an exemplary aspect the present disclosure.
FIG. 3B illustrates a graphical representation of patient-perceived efficacy of the clinical trials, in accordance with an exemplary aspect the present disclosure.
FIG. 3C illustrates a graphical representation of patient satisfaction of the clinical trials, in accordance with an exemplary aspect the present disclosure.
FIG. 3D illustrates a graphical representation of survey of the clinical trials, in accordance with an exemplary aspect the present disclosure.
To facilitate understanding, reference numerals have been used, where possible, to designate like elements common to the figures.
DETAILED DESCRIPTION
Various aspects of the present disclosure provide a method of preparing formulation and a kit for lightening hyperpigmented skin. The following description provides specific details of certain aspects of the disclosure illustrated in the drawings to provide a thorough understanding of those aspects. It should be recognized, however, that the present disclosure can be reflected in additional aspects and the disclosure may be practiced without some of the details in the following description.
The various aspects including the example aspects are now described more fully with reference to the accompanying drawings, in which the various aspects of the disclosure are shown. The disclosure may, however, be embodied in different forms and should not be construed as limited to the aspects set forth herein. Rather, these aspects are provided so that this disclosure is thorough and complete, and fully conveys the scope of the disclosure to those skilled in the art. In the drawings, the sizes of components may be exaggerated for clarity.
The subject matter of example aspects, as disclosed herein, is described with specificity to meet statutory requirements. However, the description itself is not intended to limit the scope of this patent. Rather, the inventor/inventors have contemplated that the claimed subject matter might also be embodied in other ways, to include different features or combinations of features similar to the ones described in this document, in conjunction with other technologies. Generally, the various aspects including the example aspects relate to the method of preparing formulation and a kit for lightening hyperpigmented skin.
As mentioned, there remains a need, the present disclosure relates the method of preparing formulation and the kit for lightening hyperpigmented skin. The method includes dissolving one or more ingredients in a solvent to form a lipid phase, evaporating the solvent to create a thin lipid film, adding an aqueous phase to form a liposome suspension, sonicating the suspension to achieve the size and polydispersity index, homogenizing at high speed, and adjusting the pH of the final formulation. The kit includes the final formulation.
Each and every ingredient of the formulation is commercially procured from Europe to make the formulation. No component used in the method and complete invention was procured from India.
FIG. 1 illustrates a flowchart that depicts a method (100) for preparing the formulation, in accordance with the aspect of the present disclosure. The method (100) may include:
At step 102, combining one or more ingredients, wherein one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4-8% w/v, 4-n-tert-butylresorcinol in a range of 0.05-2% w/v, quercetin in a range of 0.2-0.8% w/v, ceramides in a range of 0.05-0.7% w/v, lavender essential oil in a range of 0.05-0.7% w/v, all-trans-retinal in a range of 0.01-0.1% w/v, ethanol in a range of 0.5-3% w/v, niacinamide in a range of 0.05-4% w/v, tranexamic acid in a range of 0.05-5% w/v, glutathione in a range of 1-4% w/v, ascorbic acid in a range of 0.2-2% w/v, sodium ascorbate in a range of 0.1-3% w/v, sodium metabisulphite in a range of 0.01-0.5% w/v, glycerol in a range of 0.5-3% w/v, propylene glycol in a range of 0.5-3% w/v, xanthan gum in a range of 0.01-2% w/v, acacia in a range of 0.01-2% w/v, poloxamer 407 in a range of 0.01-0.5% w/v, and potassium sorbate in a range of 0.1-0.3% w/v.
At step 104, dissolving non-GMO sunflower phosphatidylcholine H90 in a range of 4-8% w/v, 4-n-tert-butylresorcinol in a range of 0.05-2% w/v, quercetin in a range of 0.2-0.8% w/v, ceramides in a range of 0.05-0.7% w/v, lavender essential oil in a range of 0.2-1% w/v, and all-trans-retinal in a range of 0.01-0.1% w/v in ethanol in a range of 0.5-3% w/v to obtain a mixture.
At step 106, pouring the mixture into a flask and heating the mixture at a temperature in a range of 20°C to 40°C for evaporating residual ethanol, to form a thin lipid film. In some aspects, an evaporator may be used for evaporating the residual ethanol. The evaporator may include, but are not limited to, rotary evaporator, thin film evaporator, vacuum evaporator, direct flame evaporator, or the like. Aspects of the present disclosure are intended to include or otherwise cover any type of evaporator including known, related art, and/or later developed evaporator.
At step 108, hydrating the lipid film by adding an aqueous phase, wherein the aqueous phase comprises niacinamide in a range of 0.05-4% w/v, tranexamic acid in a range of 0.05-5% w/v, glutathione in a range of 1-4% w/v, ascorbic acid in a range of 0.2-2% w/v and as sodium ascorbate in a range of 0.1-3% w/v, sodium metabisulphite in a range of 0.01-0.5% w/v, glycerol in a range of 0.5-3% w/v, propylene glycol in a range of 0.5-3% w/v, xanthan gum in a range of 0.01-2% w/v, acacia in a range of 0.01-2% w/v, poloxamer 407 in a range of 0.01-0.5% w/v, and potassium sorbate in a range of 0.01-2% w/v, and heating at a temperature in a range of 30°C to 50°C to convert the lipid film into a hydrated liposome suspension.
At step 110, sonicating the hydrated liposome suspension at a temperature of 10°C to 20°C. In some aspects, the hydrated liposome suspension may be sonicated for a time duration in a range of 5-10 minutes. In some aspects, the hydrated liposome suspension may be breakdown in a target size in a range of 250-400 nm and polydispersity index (PDI) in a range of 0.25-0.3.
At step 112, homogenizing the obtained liposome suspension at a speed of 10,000 to 15,000 rpm to further reduce liposome size and adjusting pH in a range of 5 to 5.5, to obtain a final formulation for lightening hyperpigmented skin. In some aspects, the pH is adjusted to 5.2. In some aspects, homogenizing is continued until the liposome suspension achieves a uniform particle size distribution.
At step 114, filtering the final formulation through a 0.22 µm filter.
In an embodiment, the final formulation obtained by above method may include serum 1, serum 2, and serum 3. The serum 1 may be obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, 4-n-tert-butylresorcinol in a range of 0.05 % w/v to 2 % w/v, niacinamide in a range of 0.05 % w/v to 4 % w/v, tranexamic acid in a range of 0.05 % w/v to 5 % w/v, acacia in a range of 0.01 % w/v to 0.5 % w/v, xanthan gum in a range of 0.01 % w/v to 0.5 % w/v, and potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and ultra-pure water. The serum 2 may be obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, glutathione in a range of 1 % w/v to 4 % w/v, ascorbic acid in a range of 0.2 % w/v to 2 % w/v, sodium ascorbate in a range of 0.1 % w/v to 3 % w/v, sodium metabisulfite in a range of 0.01 % w/v to 0.5 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and lavender essential oil in a range of 0.2 % w/v to 1 % w/v, and ultra-pure water. The serum 3 may be obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, all-trans-retinal in a range of 0.01 % w/v to 0.1 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, and potassium sorbate in a range of 0.01 % w/v to 2 % w/v, and ultra-pure water.
In some embodiments, a kit for lightening hyperpigmented skin is disclosed. The kit may include the formulation. The formulation may include serum 1, serum 2, and serum 3.
In some embodiments, a method for treating hyperpigmented skin is disclosed. The method may include administering the formulation. The formulation may include serum 1, serum 2, and serum 3. The method may further include applying the formulation to the hyperpigmented skin to reduce pigmentation in the affected areas of the skin.
In some embodiment, use of the formulation may be for lightening hyperpigmented skin conditions is provided.
In some embodiment, the hyperpigmented skin condition may be selected from a group that may include but are not limited to melasma, age spots, freckles, or post-inflammatory hyperpigmentation. Aspects of the present disclosure are intended to include or otherwise cover any type of hyperpigmented skin condition including known, related art, and/or later developed hyperpigmented skin condition.
In some embodiment, the formulation may be in any form. The form may include a serum, capsule, serum, gel, cream, lotion, spray, ointment, patch, or the like. Aspects of the present disclosure are intended to include or otherwise cover any type of form including known, related art, and/or later developed form.
Examples
The disclosure will now be illustrated with working examples, which is intended to illustrate the working of disclosure and not intended to take restrictively to imply any limitations on the scope of the present disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar to or equivalent to those described herein can be used in the practice of the disclosed methods and formulations, the exemplary methods, devices, and materials are described herein. It is to be understood that this disclosure is not limited to methods, and experimental conditions described, as such methods and conditions may vary.
Example 1:
A 16-week, open-label, single-arm clinical study was conducted to evaluate the efficacy, safety, and tolerability of the formulation in individuals with an mMASI score of ≤10. The formulation consisted of three serums (serum 1-3) containing quercetin, 4-n-tertbutylresorcinol, niacinamide, glutathione, ascorbic acid, retinaldehyde, and tranexamic acid, targeting various promoters in the melanogenesis pathway. The individuals were assessed at baseline, week 4, week 8, and week 12 by dermatologists and through clinical photography. Adverse events were documented at each visit, and participants' perceived efficacy and satisfaction were recorded. Additionally, the Melasma Quality of Life Survey (MELASQOL) was completed at baseline and at the end of treatment (week 12). To assess rebound pigmentation, follow-up evaluations were conducted one-month post-treatment (week 16).
Observation: The individuals were assessed at baseline, week 4, week 8, and week 12 by dermatologists and through clinical photography. Adverse events were documented at each visit, and participants' perceived efficacy and satisfaction were recorded. Additionally, the Melasma Quality of Life Survey (MELASQOL) was completed at baseline and at the end of treatment (week 12). The observations of the treatment on the individuals can be referred by Fig 2.
To assess rebound pigmentation, follow-up evaluations were conducted one-month post-treatment (week 16).
• Dermatologist-Assessed Efficacy (mMASI Scoring): Dermatologists performed Modified Melasma Area & Severity Index (mMASI) scoring at each evaluation point along with clinical photography. A progressive reduction in mMASI scores was observed throughout the study period, with a 32% reduction at week 4, 47% at week 8, and approximately 60% at week 12 compared to baseline (as shown in FIG. 3A).
• Patient-Perceived Efficacy: Participants assessed the effectiveness of the test formulations using a 5-point scale, where -1 indicated worsening, 0 indicated no improvement, and higher scores reflected increasing levels of improvement. A greater percentage of participants reported ‘marked’ or ‘moderate’ improvement at week 12 compared to week 4, while those reporting ‘mild’ improvement declined steadily over the treatment period (as shown in FIG. 3B).
• Patient Satisfaction: Participants evaluated their satisfaction with the treatment at weeks 4, 8, and 12, with ratings classified as ‘excellent,’ ‘moderately satisfied,’ or ‘not satisfied.’ An equal proportion of participants expressed satisfaction as either ‘excellent’ or ‘moderately satisfied,’ and no participants reported being ‘not satisfied’ with the formulations (as shown in FIG. 3C).
• Melasma Quality of Life (MELASQOL) Survey: The MELASQOL survey, assessing quality of life on a scale from 1 to 7, was conducted at baseline and week 12. A significant improvement in MELASQOL scores was observed at the conclusion of the 12-week treatment period, indicating enhanced quality of life for study participants (as shown in FIG. 3D).
Result: The study demonstrated a significant reduction in mMASI scores over the treatment period. mMASI stands for Modified Melasma Area and Severity Index. It is a validated scoring system widely used by dermatologist to evaluate the severity of melasma. It takes into account the extent of melasma pigmentation (area) and intensity of the pigmented patches (darkness). A 32% reduction from baseline was observed at week 4, followed by a 47% reduction at week 8, and close to 60% reduction at week 12. No, adverse events were noted by the dermatologists in any of the individuals participating in the study.
Additionally, no resistance to the treatment was observed among the participants. Compared to other depigmenting cosmeceutical formulations, either as monotherapies or in combination with antioxidants and tranexamic acid, the formulation exhibited both faster and superior efficacy. The treatment approach leveraged the lowest effective concentration of melanogenesis inhibitors while incorporating quercetin’s ability to mitigate production of senescent associated secretory phenotype (SASP) proteins by senescent cells in the epidermis and dermis, overcoming resistance commonly associated with conventional treatments.
Following discontinuation of the formulation, clinical improvement in melasma remained evident at the one-month follow-up. Importantly, there was no observable rebound in pigmentation following the cessation of application of the serums. In contrast, conventional therapies have shown a significant decline in efficacy within one month, with complete relapse to baseline levels within six months post-treatment. Moreover, some patients undergoing traditional treatments have experienced pigmentation rebound surpassing their initial condition.
Further, the participants rated their perceived efficacy as 'marked improvement' or 'moderate improvement' at the end of the study (week 12) compared to the beginning of the study (week 4). Additionally, subject satisfaction with the serums remained consistent as an equal proportion reported their satisfaction as 'excellent' or 'moderate', while none reported 'no satisfaction'. Lastly, there was a significant improvement in Melasma Quality of Life (MELASQOL) Survey, which evaluates quality of life for patients with melasma, at the conclusion of the 12-week study period when compared to baseline measurements.
Example 2
A formulation for lightening hyperpigmented skin was prepared by combining 6% w/v non-GMO sunflower phosphatidylcholine H90, 1.5% w/v 4-n-tert-butylresorcinol, 0.6% w/v quercetin, 0.4% w/v ceramides, 0.5% w/v lavender essential oil, 0.05% w/v all-trans-retinal, 2% w/v ethanol, 3% w/v niacinamide, 4% w/v tranexamic acid, 3% w/v glutathione, 1.5% w/v ascorbic acid, 2% w/v sodium ascorbate, 0.2% w/v sodium metabisulphite, 2% w/v glycerol, 2% w/v propylene glycol, 0.8% w/v xanthan gum, 0.5% w/v acacia, 0.3% w/v poloxamer 407, and 0.2% w/v potassium sorbate. The ingredients were dissolved in ethanol to obtain a mixture, which was then poured into a flask and heated at 50°C to evaporate residual ethanol, forming a thin lipid film. The lipid film was hydrated by adding an aqueous phase containing 3% w/v niacinamide, 3% w/v tranexamic acid, 2.5% w/v glutathione, 1.2% w/v ascorbic acid, 1.5% w/v sodium ascorbate, 0.1% w/v sodium metabisulphite, 1.5% w/v glycerol, 1.8% w/v propylene glycol, 0.6% w/v xanthan gum, 0.5% w/v acacia, 0.2% w/v poloxamer 407, and 0.2% w/v potassium sorbate, followed by heating at 40°C to convert the lipid film into a hydrated liposome suspension. The hydrated liposome suspension was sonicated at 15°C and homogenized at 12,000 rpm to reduce liposome size, and the pH was adjusted to 5.2 to obtain the final formulation. The final formulation included serum 1, serum 2, and serum 3.
Serum 1 was prepared by mixing 6% w/v non-GMO sunflower phosphatidylcholine H90, 2% w/v glycerol, 2% w/v ethanol, 2% w/v propylene glycol, 1% w/v 4-n-tert-butylresorcinol, 3% w/v niacinamide, 4% w/v tranexamic acid, 0.3% w/v acacia, 0.3% w/v xanthan gum, and 0.2% w/v potassium sorbate with ultra-pure water.
Serum 2 was prepared by mixing 6% w/v non-GMO sunflower phosphatidylcholine H90, 2% w/v glycerol, 2% w/v ethanol, 2% w/v propylene glycol, 0.5% w/v quercetin, 0.4% w/v ceramides, 3% w/v glutathione, 1.5% w/v ascorbic acid, 2% w/v sodium ascorbate, 0.2% w/v sodium metabisulphite, 0.2% w/v poloxamer 407, 1% w/v acacia, 0.8% w/v xanthan gum, 0.2% w/v potassium sorbate, and 0.5% w/v lavender essential oil with ultra-pure water.
Serum 3 was prepared by mixing 6% w/v non-GMO sunflower phosphatidylcholine H90, 2% w/v glycerol, 2% w/v ethanol, 2% w/v propylene glycol, 0.05% w/v all-trans-retinal, 0.5% w/v quercetin, 0.4% w/v ceramides, 0.2% w/v poloxamer 407, 1% w/v acacia, 0.8% w/v xanthan gum, and 0.2% w/v potassium sorbate with ultra-pure water.
Advantages of the present invention include:
• Rapid Onset and Enhanced Efficacy: The formulation demonstrates up to a 60% reduction in melasma within 12 weeks, exceeding the performance of conventional treatments such as topical 4% hydroquinone.
• Sustained Remission and Prevention of Rebound Pigmentation: Results are maintained post-discontinuation, with no observed rebound pigmentation following cessation of treatment.
• Targeting Cellular Senescence: The formulation addresses senescent fibroblasts, a key factor in relapse and rebound pigmentation associated with melasma treatment.
• Reduced Side Effects: Utilizing minimal effective concentrations of active agents results in improved tolerability and patient compliance.
• Multifaceted Mechanism of Action: The formulation combines depigmenting, antioxidant, anti-inflammatory, and anti-angiogenic effects.
• Liposomes with a particle size of 300 nm or below enables deeper penetration of active agents into the skin, enhancing delivery efficiency.
• A polydispersity index (PDI) of 0.3 or below ensures a homogeneous population of lipid vesicles, optimizing liposomal formulations for effective transdermal delivery.
The foregoing discussion of the present disclosure has been presented for purposes of illustration and description. It is not intended to limit the present disclosure to the form or forms disclosed herein. In the foregoing Detailed Description, for example, various features of the present disclosure are grouped together in one or more aspects, configurations, or aspects for the purpose of streamlining the disclosure. The features of the aspects, configurations, or aspects may be combined in alternate aspects, configurations, or aspects other than those discussed above. This method of disclosure is not to be interpreted as reflecting an intention, the present disclosure requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed aspect, configuration, or aspect. Thus, the following claims are hereby incorporated into this Detailed Description, with each claim standing on its own as a separate aspect of the present disclosure.

Moreover, though the description of the present disclosure has included a description
of one or more aspects, configurations, or aspects and certain variations and modifications, other variations, combinations, and modifications are within the scope of the present disclosure, e.g., as may be within the skill and knowledge of those in the art, after understanding the present disclosure. It is intended to obtain rights that include alternative aspects, configurations, or aspects to the extent permitted, including alternate, interchangeable, and/or equivalent structures, functions, ranges, or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges, or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter. , Claims:1. A method (100) of preparing a formulation for lightening hyperpigmented skin, the method comprising steps:
a. combining (102) one or more ingredients, wherein one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4-8% w/v, 4-n-tert-butylresorcinol in a range of 0.05-2% w/v, quercetin in a range of 0.2-0.8% w/v, ceramides in a range of 0.05-0.7% w/v, lavender essential oil in a range of 0.05-0.7% w/v, all-trans-retinal in a range of 0.01-0.1% w/v, ethanol in a range of 0.5-3% w/v, niacinamide in a range of 0.05-4% w/v, tranexamic acid in a range of 0.05-5% w/v, glutathione in a range of 1-4% w/v, ascorbic acid in a range of 0.2-2% w/v, sodium ascorbate in a range of 0.1-3% w/v, sodium metabisulphite in a range of 0.01-0.5% w/v, glycerol in a range of 0.5-3% w/v, propylene glycol in a range of 0.5-3% w/v, xanthan gum in a range of 0.01-2% w/v, acacia in a range of 0.01-2% w/v, poloxamer 407 in a range of 0.01-0.5% w/v, and potassium sorbate in a range of 0.1-0.3% w/v;
b. dissolving (104) non-GMO sunflower phosphatidylcholine H90 in a range of 4-8% w/v, 4-n-tert-butylresorcinol in a range of 0.05-2% w/v, quercetin in a range of 0.2-0.8% w/v, ceramides in a range of 0.05-0.7% w/v, lavender essential oil in a range of 0.2-1% w/v, and all-trans-retinal in a range of 0.01-0.1% w/v in ethanol in a range of 0.5-3% w/v to obtain a mixture;
c. pouring (106) the mixture into a flask and heating the mixture at a temperature in a range of 20°C to 40°C for evaporating residual ethanol, to form a thin lipid film;
d. hydrating (108) the lipid film by adding an aqueous phase, wherein the aqueous phase comprises niacinamide in a range of 0.05-4% w/v, tranexamic acid in a range of 0.05-5% w/v, glutathione in a range of 1-4% w/v, ascorbic acid in a range of 0.2-2% w/v and as sodium ascorbate in a range of 0.1-3% w/v, sodium metabisulphite in a range of 0.01-0.5% w/v, glycerol in a range of 0.5-3% w/v, propylene glycol in a range of 0.5-3% w/v, xanthan gum in a range of 0.01-2% w/v, acacia in a range of 0.01-2% w/v, poloxamer 407 in a range of 0.01-0.5% w/v, and potassium sorbate in a range of 0.01-2% w/v, and heating at a temperature in a range of 30°C to 50°C to convert the lipid film into a hydrated liposome suspension;
e. sonicating (110) the hydrated liposome suspension at a temperature of 10°C to 20°C; and
f. homogenizing (112) the obtained liposome suspension at a speed of 10,000 to 15,000 rpm to further reduce liposome size and adjusting pH in a range of 5 to 5.5, to obtain a final formulation for lightening hyperpigmented skin.

2. The method (100) as claimed in claim 1, wherein the method (100) further comprising filtering (114) the final formulation through a 0.22 µm filter.

3. The method (100) as claimed in claim 1, wherein the formulation comprising;
a. serum 1 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, 4-n-tert-butylresorcinol in a range of 0.05 % w/v to 2 % w/v, niacinamide in a range of 0.05 % w/v to 4 % w/v, tranexamic acid in a range of 0.05 % w/v to 5 % w/v, acacia in a range of 0.01 % w/v to 0.5 % w/v, xanthan gum in a range of 0.01 % w/v to 0.5 % w/v, and potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and ultra-pure water;
b. serum 2 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, glutathione in a range of 1 % w/v to 4 % w/v, ascorbic acid in a range of 0.2 % w/v to 2 % w/v, sodium ascorbate in a range of 0.1 % w/v to 3 % w/v, sodium metabisulfite in a range of 0.01 % w/v to 0.5 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and lavender essential oil in a range of 0.2 % w/v to 1 % w/v, and ultra-pure water;
c. serum 3 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, all-trans-retinal in a range of 0.01 % w/v to 0.1 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, and potassium sorbate in a range of 0.01 % w/v to 2 % w/v, and ultra-pure water.

4. A kit comprising for lightening hyperpigmented skin, the kit comprising:
a formulation comprising:
serum 1 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, 4-n-tert-butylresorcinol in a range of 0.05 % w/v to 2 % w/v, niacinamide in a range of 0.05 % w/v to 4 % w/v, tranexamic acid in a range of 0.05 % w/v to 5 % w/v, acacia in a range of 0.01 % w/v to 0.5 % w/v, xanthan gum in a range of 0.01 % w/v to 0.5 % w/v, and potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and ultra-pure water;
serum 2 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, glutathione in a range of 1 % w/v to 4 % w/v, ascorbic acid in a range of 0.2 % w/v to 2 % w/v, sodium ascorbate in a range of 0.1 % w/v to 3 % w/v, sodium metabisulfite in a range of 0.01 % w/v to 0.5 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and lavender essential oil in a range of 0.2 % w/v to 1 % w/v, and ultra-pure water;
serum 3 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, all-trans-retinal in a range of 0.01 % w/v to 0.1 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, and potassium sorbate in a range of 0.01 % w/v to 2 % w/v, and ultra-pure water.

5. A formulation for lightening hyperpigmented skin, wherein the formulation comprising:
a. serum 1 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, 4-n-tert-butylresorcinol in a range of 0.05 % w/v to 2 % w/v, niacinamide in a range of 0.05 % w/v to 4 % w/v, tranexamic acid in a range of 0.05 % w/v to 5 % w/v, acacia in a range of 0.01 % w/v to 0.5 % w/v, xanthan gum in a range of 0.01 % w/v to 0.5 % w/v, and potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and ultra-pure water;
b. serum 2 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, glutathione in a range of 1 % w/v to 4 % w/v, ascorbic acid in a range of 0.2 % w/v to 2 % w/v, sodium ascorbate in a range of 0.1 % w/v to 3 % w/v, sodium metabisulfite in a range of 0.01 % w/v to 0.5 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and lavender essential oil in a range of 0.2 % w/v to 1 % w/v, and ultra-pure water;
c. serum 3 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, all-trans-retinal in a range of 0.01 % w/v to 0.1 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, and potassium sorbate in a range of 0.01 % w/v to 2 % w/v, and ultra-pure water;
obtained by a method comprising;
a. combining one or more ingredients, wherein one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4-8% w/v, 4-n-tert-butylresorcinol in a range of 0.05-2% w/v, quercetin in a range of 0.2-0.8% w/v, ceramides in a range of 0.05-0.7% w/v, lavender essential oil in a range of 0.05-0.7% w/v, all-trans-retinal in a range of 0.01-0.1% w/v, ethanol in a range of 0.5-3% w/v, niacinamide in a range of 0.05-4% w/v, tranexamic acid in a range of 0.05-5% w/v, glutathione in a range of 1-4% w/v, ascorbic acid in a range of 0.2-2% w/v, sodium ascorbate in a range of 0.1-3% w/v, sodium metabisulphite in a range of 0.01-0.5% w/v, glycerol in a range of 0.5-3% w/v, propylene glycol in a range of 0.5-3% w/v, xanthan gum in a range of 0.01-2% w/v, acacia in a range of 0.01-2% w/v, poloxamer 407 in a range of 0.01-0.5% w/v, and potassium sorbate in a range of 0.1-0.3% w/v;
b. dissolving non-GMO sunflower phosphatidylcholine H90 in a range of 4-8% w/v, 4-n-tert-butylresorcinol in a range of 0.05-2% w/v, quercetin in a range of 0.2-0.8% w/v, ceramides in a range of 0.05-0.7% w/v, lavender essential oil in a range of 0.2-1% w/v, and all-trans-retinal in a range of 0.01-0.1% w/v in ethanol in a range of 0.5-3% w/v to obtain a mixture;
c. pouring the mixture into a flask and heating the mixture at a temperature in a range of 20°C to 40°C for evaporating residual ethanol, to form a thin lipid film;
d. hydrating the lipid film by adding an aqueous phase, wherein the aqueous phase comprises niacinamide in a range of 0.05-4% w/v, tranexamic acid in a range of 0.05-5% w/v, glutathione in a range of 1-4% w/v, ascorbic acid in a range of 0.2-2% w/v and as sodium ascorbate in a range of 0.1-3% w/v, sodium metabisulphite in a range of 0.01-0.5% w/v, glycerol in a range of 0.5-3% w/v, propylene glycol in a range of 0.5-3% w/v, xanthan gum in a range of 0.01-2% w/v, acacia in a range of 0.01-2% w/v, poloxamer 407 in a range of 0.01-0.5% w/v, and potassium sorbate in a range of 0.01-2% w/v, and heating at a temperature in a range of 30°C to 50°C to convert the lipid film into a hydrated liposome suspension;
e. sonicating the hydrated liposome suspension at a temperature of 10°C to 20°C; and
f. homogenizing the obtained liposome suspension at a speed of 10,000 to 15,000 rpm to further reduce liposome size and adjusting pH in a range of 5 to 5.5, to obtain a final formulation for lightening hyperpigmented skin.

6. A method for treating hyperpigmented skin, the method comprising:
administering a formulation comprising:
serum 1 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, 4-n-tert-butylresorcinol in a range of 0.05 % w/v to 2 % w/v, niacinamide in a range of 0.05 % w/v to 4 % w/v, tranexamic acid in a range of 0.05 % w/v to 5 % w/v, acacia in a range of 0.01 % w/v to 0.5 % w/v, xanthan gum in a range of 0.01 % w/v to 0.5 % w/v, and potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and ultra-pure water;
serum 2 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, glutathione in a range of 1 % w/v to 4 % w/v, ascorbic acid in a range of 0.2 % w/v to 2 % w/v, sodium ascorbate in a range of 0.1 % w/v to 3 % w/v, sodium metabisulfite in a range of 0.01 % w/v to 0.5 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and lavender essential oil in a range of 0.2 % w/v to 1 % w/v, and ultra-pure water;
serum 3 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, all-trans-retinal in a range of 0.01 % w/v to 0.1 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, and potassium sorbate in a range of 0.01 % w/v to 2 % w/v, and ultra-pure water; and
applying the formulation to the hyperpigmented skin to reduce pigmentation in the affected areas of the skin.

7. The method as claimed in claim 6, wherein the hyperpigmented skin condition is selected from a group comprising melasma, age spots, freckles, or post-inflammatory hyperpigmentation.

8. Use of a formulation comprising:
serum 1 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, 4-n-tert-butylresorcinol in a range of 0.05 % w/v to 2 % w/v, niacinamide in a range of 0.05 % w/v to 4 % w/v, tranexamic acid in a range of 0.05 % w/v to 5 % w/v, acacia in a range of 0.01 % w/v to 0.5 % w/v, xanthan gum in a range of 0.01 % w/v to 0.5 % w/v, and potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and ultra-pure water;
serum 2 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, glutathione in a range of 1 % w/v to 4 % w/v, ascorbic acid in a range of 0.2 % w/v to 2 % w/v, sodium ascorbate in a range of 0.1 % w/v to 3 % w/v, sodium metabisulfite in a range of 0.01 % w/v to 0.5 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, potassium sorbate in a range of 0.1 % w/v to 0.3 % w/v, and lavender essential oil in a range of 0.2 % w/v to 1 % w/v, and ultra-pure water;
serum 3 obtained by mixing one or more ingredients comprising non-GMO sunflower phosphatidylcholine H90 in a range of 4 % w/v to 8 % w/v, glycerol in a range of 0.5 % w/v to 3 % w/v, ethanol in a range of 0.5 % w/v to 3 % w/v, propylene glycol in a range of 0.5 % w/v to 3 % w/v, all-trans-retinal in a range of 0.01 % w/v to 0.1 % w/v, quercetin in a range of 0.2 % w/v to 0.8 % w/v, ceramides in a range of 0.05 % w/v to 0.7 % w/v, poloxamer 407 in a range of 0.01 % w/v to 0.5 % w/v, acacia in a range of 0.2 % w/v to 2 % w/v, xanthan gum in a range of 0.01 % w/v to 2 % w/v, and potassium sorbate in a range of 0.01 % w/v to 2 % w/v, and ultra-pure water;
for lightening hyperpigmented skin.